Looking ahead to 2030, our model projects BNTX could trade at an average price of $253.49, with a potential range between $190.12 and $316.86. This represents a potential 188.7% return from today's ...

BioNTech (BNTX) stock was under pressure on May 5 after the multinational announced plans to eliminate up to 1,860 roles as it continues to grapple with declining COVID-19 vaccine sales. The selloff ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

Fintel reports that on November 10, 2025, HC Wainwright & Co. maintained coverage of BioNTech SE - Depositary Receipt (NasdaqGS:BNTX) with a Buy recommendation. As of November 9, 2025, the average one ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. At a $27.6B market cap and ~$11B enterprise value, BNTX's ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which ...

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...